Starna Therapeutics signs Pfizer licensing agreement worth up to $2.6 billion
Biotechnology company Starna Therapeutics has entered into a licensing agreement with Pfizer, reported on 20 November, with potential payments of up to $2.6 billion. The agreement gives Pfizer access to specialist drug development technology and creates a route towards future commercial development. HPC could identify biotechnology companies with licensing potential, pharmaceutical partners and investors interested in medical research opportunities.
If you are interested to enquire further, please fill in the form below with your details and one of our consultants will contact you shortly.
Get in Touch
We’ll get back to you shortly.